Literature DB >> 15741264

Growth hormone replacement is important for the restoration of parathyroid hormone sensitivity and improvement in bone metabolism in older adult growth hormone-deficient patients.

H D White1, A M Ahmad, B H Durham, A Patwala, P Whittingham, W D Fraser, J P Vora.   

Abstract

Alterations in PTH circadian rhythm and PTH target-organ sensitivity exist in adult GH-deficient (AGHD) patients and may underlie the pathogenesis of AGHD-related osteoporosis. GH replacement (GHR) results in increased bone mineral density, but its benefit in AGHD patients over 60 yr old has been debated. To examine the effect of age on changes in PTH circadian rhythm and target-organ sensitivity after GHR, we recruited 22 AGHD patients (12 were <60 yr of age, and 10 were >60 yr of age). Half-hourly blood samples were collected for PTH, calcium, phosphate, nephrogenous cAMP (marker of renal PTH activity), type-I collagenbeta C-telopeptide (bone resorption marker), and procollagen type-I amino-terminal propeptide (bone formation marker) before and after 1, 3, 6, and 12 months of treatment with GHR. Significant PTH circadian rhythms were present in both age groups throughout the study. After GHR, PTH decreased and nephrogenous cAMP, adjusted calcium, and bone turnover markers increased in both groups, suggesting increased PTH target-organ sensitivity. In younger patients, the changes were significant after 1 month of GHR, but, in older patients, the changes were delayed until 3 months, with maximal changes at 12 months. Older AGHD patients derive benefit from GHR in terms of improvement in PTH sensitivity and bone metabolism. Their response appears delayed and may explain why previous studies have not shown a positive effect of GHR on bone mineral density in older AGHD patients.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15741264     DOI: 10.1210/jc.2004-1650

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  11 in total

1.  Prevalence of osteoporosis and vertebral fractures in acromegalic patients.

Authors:  Giuseppina Padova; Graziella Borzì; Laura Incorvaia; Guido Siciliano; Valentina Migliorino; Mario Vetri; Patrizia Tita
Journal:  Clin Cases Miner Bone Metab       Date:  2011-09

Review 2.  Insulin like growth factor-I: a critical mediator of the skeletal response to parathyroid hormone.

Authors:  Daniel D Bikle; Yongmei Wang
Journal:  Curr Mol Pharmacol       Date:  2012-06       Impact factor: 3.339

Review 3.  Skeletal effects of growth hormone and insulin-like growth factor-I therapy.

Authors:  Richard C Lindsey; Subburaman Mohan
Journal:  Mol Cell Endocrinol       Date:  2015-09-25       Impact factor: 4.102

Review 4.  Growth hormone, insulin-like growth factors, and the skeleton.

Authors:  Andrea Giustina; Gherardo Mazziotti; Ernesto Canalis
Journal:  Endocr Rev       Date:  2008-04-24       Impact factor: 19.871

5.  OPPORTUNITY: a randomized clinical trial of growth hormone on outcome in hemodialysis patients.

Authors:  Joel D Kopple; Alfred K Cheung; Jens Sandahl Christiansen; Christian Born Djurhuus; Meguid El Nahas; Bo Feldt-Rasmussen; Martin Lange; William E Mitch; Christoph Wanner; Jonas Wiedemann; T Alp Ikizler
Journal:  Clin J Am Soc Nephrol       Date:  2008-11       Impact factor: 8.237

Review 6.  Effect of GH/IGF-1 on Bone Metabolism and Osteoporsosis.

Authors:  Vittorio Locatelli; Vittorio E Bianchi
Journal:  Int J Endocrinol       Date:  2014-07-23       Impact factor: 3.257

7.  IGF-I induced phosphorylation of PTH receptor enhances osteoblast to osteocyte transition.

Authors:  Tao Qiu; Janet L Crane; Liang Xie; Lingling Xian; Hui Xie; Xu Cao
Journal:  Bone Res       Date:  2018-02-26       Impact factor: 13.567

8.  Age-related increases in parathyroid hormone may be antecedent to both osteoporosis and dementia.

Authors:  Eric R Braverman; Thomas J H Chen; Amanda L C Chen; Vanessa Arcuri; Mallory M Kerner; Anish Bajaj; Javier Carbajal; Dasha Braverman; B William Downs; Kenneth Blum
Journal:  BMC Endocr Disord       Date:  2009-10-13       Impact factor: 2.763

Review 9.  GH Replacement in the Elderly: Is It Worth It?

Authors:  Silvia Ricci Bitti; Marta Franco; Manuela Albertelli; Federico Gatto; Lara Vera; Diego Ferone; Mara Boschetti
Journal:  Front Endocrinol (Lausanne)       Date:  2021-06-15       Impact factor: 5.555

10.  Increased vertebral morphometric fracture in patients with postsurgical hypoparathyroidism despite normal bone mineral density.

Authors:  Maira L Mendonça; Francisco A Pereira; Marcello H Nogueira-Barbosa; Lucas M Monsignore; Sara R Teixeira; Plauto Ca Watanabe; Lea Mz Maciel; Francisco Ja de Paula
Journal:  BMC Endocr Disord       Date:  2013-01-03       Impact factor: 2.763

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.